466 completed, 109 terminated, 30 recruiting, 24 withdrawn. 198 Phase 1, 155 Phase 2, 115 Phase 3, 62 Phase 4, 19 Not applicable.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 1 | 198 | Completed 163, Terminated 24, Recruiting 5, Withdrawn 4, Active not recruiting 2 |
| Phase 2 | 155 | Completed 101, Terminated 38, Withdrawn 8, Recruiting 5, Active not recruiting 3 |
| Phase 3 | 115 | Completed 61, Terminated 28, Active not recruiting 11, Recruiting 5, Withdrawn 5, Enrolling by invitation 3, Not yet recruiting 1, Unknown 1 |
| Phase 4 | 62 | Completed 42, Terminated 9, Withdrawn 7, Unknown 3, Active not recruiting 1 |
| Not applicable | 19 | Completed 15, Recruiting 2, Unknown 2 |
| Early Phase 1 | 2 | Completed 2 |
Follow Biogen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Diroximel Fumarate, Dimethyl Fumarate, Fingolimod - Relapsing Forms of Multiple Sclerosis | Phase 3 | Not yet recruiting | Biogen | 185 | 2026-11-16 | 2026-03-19 |
A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
Salanersen, Sham Procedure - Muscular Atrophy, Spinal | Phase 3 | Recruiting | Biogen | 42 | 2026-10-31 | 2026-10-15 |
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
Omaveloxolone - Friedreich Ataxia | | Recruiting | Biogen | 10 | 2026-10-26 | 2026-07-10 |
A Study to Learn More About Friedrich's Ataxia in People Living in the Gulf Cooperation Council (GCC) Region of the World
Friedreich's Ataxia | | Not yet recruiting | Biogen | 40 | 2026-10-15 | 2026-10-21 |
A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)
BIIB147, Placebo - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Recruiting | Biogen | 69 | 2026-10-07 | 2026-10-19 |
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
Salanersen - Spinal Muscular Atrophy | Phase 3 | Recruiting | Biogen | 90 | 2026-09-08 | 2026-10-02 |
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
Felzartamab, Placebo - Graves' Disease | Phase 2 | Recruiting | Biogen | 60 | 2026-07-30 | 2026-10-14 |
A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo
BIIB144, Placebo - Healthy Volunteer | Phase 1 | Recruiting | Biogen | 48 | 2026-07-21 | 2026-07-27 |
Cardiac Output and Fatigue in Friedreich's Ataxia
Aerobic Exercise - Friedreich's Ataxia | Not applicable | Recruiting | Scott Barbuto | 30 | 2026-07-15 | 2026-09-22 |
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
Salanersen - Muscular Atrophy, Spinal | Phase 3 | Recruiting | Biogen | 30 | 2026-04-28 | 2026-10-21 |
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
Felzartamab - Antibody-mediated Rejection, Microvascular Inflammation | Phase 3 | Enrolling by invitation | Biogen | 201 | 2026-04-16 | 2026-10-09 |
Gait and Bone Health in SMA
Spinal Muscular Atrophy Type 3, Ambulatory Spinal Muscular Atrophy | | Recruiting | Jacqueline Montes | 22 | 2026-03-05 | 2026-03-18 |
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
Felzartamab, Placebo - Microvascular Inflammation | Phase 2 | Recruiting | Biogen | 81 | 2026-01-05 | 2026-10-16 |
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)
Tofersen - Amyotrophic Lateral Sclerosis | | Recruiting | Biogen | 125 | 2026-01-02 | 2026-04-09 |
Tofersen in Non-SOD1 ALS
Tofersen - ALS (Amyotrophic Lateral Sclerosis) | Phase 2 | Recruiting | Washington University School of Medicine | 30 | 2025-12-29 | 2026-06-25 |
A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone
Zuranolone - Postpartum Depression | | Recruiting | Biogen | 300 | 2025-12-22 | 2026-09-08 |
A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants
BIIB145, Placebo - Healthy Volunteer | Phase 1 | Recruiting | Biogen | 104 | 2025-12-18 | 2026-02-06 |
A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55
Omaveloxolone - Healthy Volunteer | Phase 1 | Completed | Biogen | 70 | 2025-12-12 | 2026-05-14 |
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
Tofersen - Amyotrophic Lateral Sclerosis | Phase 4 | Active not recruiting | Biogen | 12 | 2025-12-11 | 2026-08-13 |
A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55
Omaveloxolone, Omeprazole - Healthy Volunteer | Phase 1 | Completed | Biogen | 22 | 2025-09-02 | 2025-10-23 |
Showing 20 of 672. Sign in to see all of them.
Conditions studied
Multiple Sclerosis (164) · Multiple Sclerosis, Relapsing-Remitting (91) · Muscular Atrophy, Spinal (37) · Arthritis, Rheumatoid (21) · Alzheimer Disease (19) · Lymphoma, Non-Hodgkin (17) · Recurrence (17) · Amyotrophic Lateral Sclerosis (15) · Parkinson Disease (12) · Crohn Disease (11) · Leukemia, Lymphocytic, Chronic, B-Cell (11) · Cognitive Dysfunction (10) · Lymphoma (9) · Renal Insufficiency, Chronic (9) · Depressive Disorder, Major (8)
Interventions
Natalizumab (69) · Dimethyl Fumarate (57) · Interferon beta-1a (43) · Rituximab (34) · bardoxolone methyl (24) · nusinersen (20) · vixotrigine (20) · omaveloxolone (19) · peginterferon beta-1a (18) · zuranolone (16) · PF-04958242 (14) · ibritumomab tiuxetan (13) · aducanumab (11) · 4-Aminopyridine (10) · Alefacept (10)
Countries
United States (455) · Germany (129) · United Kingdom (127) · Canada (103) · France (98) · Spain (87) · Italy (86) · Belgium (76) · Poland (68) · Australia (67) · Czechia (63) · Netherlands (54) · Japan (42) · Sweden (39) · Denmark (35)
Top investigators
John F Foley, MD (6) · Michael Panzara, MD, MPH (3) · Alice Gottlieb, MD, PhD (2) · Danna Jennings, MD (2) · Felipe Samaniego, MD (2) · Henrik B Jensen, MD (2) · John D. Hainsworth, MD (2) · Michelle Valentine, DO (2)
Results publications
PMID 31420846, PMID 27411694, PMID 30918100, PMID 24131282, PMID 26932146, PMID 27939059, PMID 32426039, PMID 37652990, PMID 38940656, PMID 42841310, PMID 16267322, PMID 26049148, PMID 26526385, PMID 26823478, PMID 27733070, PMID 28751099, PMID 28770420, PMID 30194931, PMID 31901758, PMID 33782940, PMID 34807243, PMID 36129998, PMID 36600109, PMID 37061656, PMID 37173129, PMID 37916745, PMID 38087949, PMID 38165296, PMID 38705943, PMID 38878121, PMID 39570545, PMID 40042496, PMID 40444214, PMID 40680102, PMID 41661214, PMID 15304586, PMID 16510744, PMID 16510745, PMID 17588298, PMID 18050221, PMID 18071030, PMID 18512710, PMID 18635429, PMID 18970976, PMID 18981007, PMID 19073949, PMID 19344412, PMID 19525191, PMID 19731307, PMID 19843887
NIH funding
2015 (20), 2017 (13), 2023 (12), 2014 (11), 2016 (10), 2019 (8), 2018 (7), 2025 (5), 2008 (3), 2009 (2), UL1RR024150 (2), P01CA066726 (1), R01AG054029 (1), R01AG061848 (1), R01AR061298 (1)